EUVIMEDEUVIMED entdecken
Crossref

Age-male-albumin-bilirubin-platelet score stratifies hepatocellular carcinoma risk after sustained virological response in hepatitis C-related compensated advanced chronic liver disease

Sirajuk Khongviwatsathien, Tawesak Tanwandee

World Journal of Hepatology · 27.08.2026 · 18 (8)

DOI: 10.4254/wjh.124474 ↗

Kurz gefasst

Fachartikel in der Zeitschrift World Journal of Hepatology, online erschienen am 27.08.2026. Verfasst von Sirajuk Khongviwatsathien und 1 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Hepatocellular carcinoma (HCC) remains an important long-term complication after sustained virological response (SVR) in patients with hepatitis C virus (HCV)-related compensated advanced chronic liver disease (cACLD). Current guidelines generally recommend lifelong semiannual surveillance for patients with advanced fibrosis or cirrhosis; however, the residual risk of HCC after viral eradication is heterogeneous. We hypothesized that simple noninvasive scores could identify a very-low-risk subgroup suitable for individualized surveillance intensity. AIM To compare the performance of noninvasive scores for predicting HCC after SVR and to identify a very-low-risk subgroup. METHODS This single-center retrospective cohort study included 571 adults with HCV-related cACLD who achieved SVR at 12 weeks after treatment completion following interferon-free sofosbuvir-based direct-acting antiviral therapy between 2013 and 2023. The fibrosis-4 index, aspartate aminotransferase-to-platelet ratio index, albumin-bilirubin score, and age-male-albumin-bilirubin-platelet (aMAP) score were calculated. HCC risk was evaluated using Kaplan-Meier analysis, Cox proportional hazards regression, and time-dependent receiver operating characteristic curves at 1 year, 3 years, 5 years, and 8 years. RESULTS During a median follow-up of 4.59 years, 78 patients (13.7%) developed de novo HCC [annual incidence rate: 3.12%; 95% confidence interval (CI): 2.50-3.80]. Compared with those who did not develop HCC, patients who developed HCC had higher baseline liver stiffness, higher prevalence of diabetes mellitus and esophageal varices, lower platelet counts and albumin levels, and higher bilirubin levels. Among the evaluated scores, the aMAP score showed the highest discriminatory performance, with an 8-year area under the receiver operating characteristic curve of 0.74 (95%CI: 0.67-0.80). An exploratory aMAP threshold of < 55 identified 18.6% of patients with no observed HCC events, whereas patients with an aMAP score ≥ 60 had the highest annual HCC incidence of 6.42% per year. CONCLUSION The aMAP score effectively stratifies the risk of HCC after SVR and may support individualized surveillance intensity in patients with HCV-related cACLD. However, the exploratory aMAP threshold requires external validation.

Zitieren

APA

Khongviwatsathien, S., & Tanwandee, T. (2026). Age-male-albumin-bilirubin-platelet score stratifies hepatocellular carcinoma risk after sustained virological response in hepatitis C-related compensated advanced chronic liver disease. World Journal of Hepatology, 18(8). https://doi.org/10.4254/wjh.124474

Vancouver

Khongviwatsathien S, Tanwandee T. Age-male-albumin-bilirubin-platelet score stratifies hepatocellular carcinoma risk after sustained virological response in hepatitis C-related compensated advanced chronic liver disease. World Journal of Hepatology. 2026;18(8). doi:10.4254/wjh.124474

BibTeX
@article{Khongviwatsathien2026,
  author = {Khongviwatsathien, Sirajuk and Tanwandee, Tawesak},
  title = {Age-male-albumin-bilirubin-platelet score stratifies hepatocellular carcinoma risk after sustained virological response in hepatitis C-related compensated advanced chronic liver disease},
  journal = {World Journal of Hepatology},
  year = {2026},
  volume = {18},
  number = {8},
  doi = {10.4254/wjh.124474}
}
Kostenlos starten →